TargetBeta
ATM
ATM serine/threonine kinase · also TEL1, TELO1, ATA, ATDC · Armadillo like helical domain containing
3 programs in company-led studies act on ATM, from 3 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| ATM Inhibitor SYH2051rule | CSPC Pharmaceutical Group | phase 2 | 33 running | – | NCIt |
| AZD1390 | AstraZeneca | phase 1 | 31 running | – | a judged reading |
| TQB3117 | Sino Biopharmaceutical | phase 1 | 11 running | – | the company's pipeline |
Conditions their studies are in
- Breast Neoplasms, 1 program
- Glioblastoma, 1 program
- Head and Neck Neoplasms, 1 program
- Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jun 15, 2027ATM Inhibitor SYH2051 · CSPC Pharmaceutical Group · phase 2 · NCT06775236
- Apr 12, 2028AZD1390 · AstraZeneca · phase 1 · NCT07643870
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.